A fixed-dose randomized controlled trial of olanzapine for psychosis in Parkinson disease.

ABSTRACT:

Background

Psychosis is a common and debilitating side effect of long-term dopaminergic treatment of Parkinson disease (PD). While clozapine is an effective treatment, the need for blood monitoring has limited its first-line use. 

Objective

Since olanzapine shows similar receptor affinity to clozapine, we hypothesized that it might be an effective alternative to clozapine for treatment of drug-induced psychosis (DIP) in PD, and that lower doses than usual might make it tolerable.

Methods

In 1998-2003 we conducted a four-week, double-blind, placebo-controlled, parallel group, fixed-dose trial of olanzapine (0, 2.5mg, or 5mg) in 23 PD patients with DIP while allowing for clinically realistic dose adjustments of dopaminomimetic mid-study. The primary outcome measures wer

SUBMITTER: Nichols MJ 

PROVIDER: S-EPMC3907164 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature